



# 4Q and full-year 2021 Financial results

## 4Q 2021

<b>Worldwide sales</b>	<b>GAAP EPS</b>	<b>Non-GAAP EPS</b>
<b>\$13.5 billion</b>	<b>\$1.51</b>	<b>\$1.80</b>

Anticipates full-year 2022 worldwide sales to be between \$56.1 billion and \$57.6 billion

Expects full-year 2022 GAAP EPS to be between \$5.76 and \$5.91; expects Non-GAAP EPS to be between \$7.12 and \$7.27

### Key growth drivers

#### Oncology

**KEYTRUDA**<sup>®</sup> (pembrolizumab) injection 100 mg Higher sales and continued uptake globally



#### Vaccines

**GARDASIL**<sup>®</sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] + **GARDASIL**<sup>®</sup> 9 [Human Papillomavirus 9-valent Vaccine, Recombinant]

Growth driven by strong global demand, particularly in China, which also benefitted from increased supply

#### Hospital Acute Care

**bridion**<sup>®</sup> (sugammadex) injection 100 mg/mL Growth driven by higher demand globally

#### Animal Health

**MSD** Animal Health Growth driven by higher sales of companion animal products across geographies and species



“Our business achieved strong revenue and earnings growth this quarter and for the full year. Throughout 2021, we invested in the discovery, development, production and commercialization of medicines and vaccines, furthering the sustainability of our business.

We enter 2022 with strong momentum and are moving with speed to bring forward innovations that address critical unmet needs and contribute to global health. This remains at the core of our strategy, and why we are focused on benefitting the patients we serve, and in turn creating long-term value for our shareholders.”

**Rob Davis**  
Chief Executive Officer and President

Creating long-term value for patients, employees and shareholders